PDCD1 and cancer: The use of monoclonal antibodies directed against the immune checkpoints CTLA4 (cytotoxic T-lymphocyte antigen 4, ipilimumab) and anti-PD-1 (programmed cell death protein 1, nivolumab and pembrolizumab) significantly improved both the recurrence-free survival and OS of cancer patients.